Hot Stocks: Brokerages on Orchid Pharma, D-Mart, NOCIL and Chola Investment

December 8, 2023

Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).

More To Explore

F&O Talk| Indian markets in mature uptrend, Nifty now eyeing 26k: Rahul Ghose

Markets snapped their five-week-long consolidation trend, driven by improving global cues, easing geopolitical concerns, and a renewed uptick in foreign institutional investor (FII) buying during

June 29, 2025

Mcap of nine of top-10 most valued firms surges by Rs 2.34 lakh crore; Reliance biggest gainer

Nine of the top-10 most valued firms together added Rs 2,34,565.53 crore in market valuation last week, with Reliance Industries emerging as the biggest gainer,

June 29, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003